AHMED NADIM
SEC CIK 1731193 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | Pres, CEO, Dir | 390.8K | $100.3K | $794.2K | 15 | 2022-06-06 | 2026-02-24 |
Most active insiders at CGEM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 10% | $11.93M | — |
| 2 | Michaelson Jennifer | CSO | — | $1.62M |
| 3 | Nichols Weston | 10% | $1.39M | — |
| 4 | AHMED NADIM | Pres, CEO, Dir | — | $518.0K |
| 5 | Jones Jeffrey Alan | Chief Medical Off | — | $178.9K |
| 6 | SUMER JACQUELYN L | CLO | — | $136.7K |
| 7 | Fenton Mary Kay | CFO | — | $59.9K |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-25 | 2026-02-24 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $14.47 | -13.5K | 390.8K | -3% | -$195.6K | |
| 2026-02-23 | 2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $13.62 | -16.4K | 404.3K | -4% | -$223.1K | |
| 2025-12-29 | 2025-12-23 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $10.01 | -9,922 | 420.7K | -2% | -$99.3K | |
| 2025-02-27 | 2025-02-25 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $8.53 | -12.5K | 430.6K | -3% | -$106.9K | |
| D | 2025-02-21 | 2025-02-19 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | A - Grant | $0.00 | +180.0K | 443.1K | +68% | $0 |
| 2024-12-27 | 2024-12-24 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $11.87 | -8,400 | 263.1K | -3% | -$99.7K | |
| D | 2024-02-23 | 2024-02-22 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | A - Grant | $0.00 | +160.0K | 271.6K | +143% | $0 |
| 2023-12-27 | 2023-12-26 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $9.24 | -4,272 | 111.5K | -4% | -$39.5K | |
| 2023-06-29 | 2023-06-28 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $11.40 | -759 | 115.8K | -0.7% | -$8,653 | |
| 2023-05-24 | 2023-05-23 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $9.15 | -707 | 116.6K | -0.6% | -$6,469 | |
| 2023-04-26 | 2023-04-25 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $10.59 | -716 | 117.3K | -0.6% | -$7,582 | |
| 2023-03-27 | 2023-03-23 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | S - Sale | $10.51 | -706 | 118.0K | -0.6% | -$7,420 | |
| D | 2023-02-23 | 2023-02-22 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | A - Grant | $0.00 | +109.0K | 118.7K | +1,123% | $0 |
| 2022-07-05 | 2022-06-30 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | A - Grant | $10.90 | +1,620 | 9,710 | +20% | +$17.7K | |
| 2022-06-07 | 2022-06-06 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Pres, CEO, Dir | P - Purchase | $12.40 | +8,090 | 8,090 | New | +$100.3K |
Purchase Sale Sale after option exercise All abbreviations